• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys275Phe (c.824G>T); ClinVar=VCV000376582; Zygosity=Homozygous (PubMed=8725545; PubMed=8782485; PubMed=29970484).
  

DOI=10.1016/B978-0-12-333530-2.50007-1
Thomas E. Carey;
Head and neck tumor cell lines.
(In book chapter) Atlas of human tumor cell lines; Hay, Robert J. & Park, Jae-Gahb & Gazdar, Adi F. (eds.); pp.79-120; Academic Press; New York; USA (1994)

PubMed=8725545; DOI=10.3109/00016489609137854
Kirsi Pekkola-Heino, Kristina Servomaa, Anne Kiuru, Reidar Grenman;
Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma.
Acta Oto-Laryngol. 116:341-344(1996)

PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x
Kristina Servomaa, Anne Kiuru, Reidar Grenman, Kirsi Pekkola-Heino, Jaakko O. Pulkkinen, Tapio Rytomaa;
p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines.
Cell Prolif. 29:219-230(1996)

PubMed=9187133
Tero Soukka, Marko Salmi, Heikki Joensuu, Lan Hakkinen, Petri Sointu, Leena Koulu, Kirsti Kalimo, Pekka Klemi, Reidar Grenman, Sirpa T. Jalkanen;
Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.
Cancer Res. 57:2281-2289(1997)

PubMed=17312569; DOI=10.1002/hed.20478
Charles J. Lin, Jennifer Rubin Grandis, Thomas E. Carey, Susanne M. Gollin, Theresa L. Whiteside, Wayne M. Koch, Robert Louis Ferris, Stephen Y. Lai;
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733
Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumagi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grenman, Stina M. Syrjanen, Olli-Pekka Kallioniemi ...Show all 15 authors... , Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni; Show fewer authors
Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.
Mol. Cancer Ther. 17:2060-2071(2018)